Zai Lab 10-Q: Q3 Revenue Falls 7% to $108.2M, Net Loss Widens to $46.1M
ZLAB sits 45% above its 52-week low of $15.96.
Summary
Zai Lab's Q3 10-Q confirms revenue of $108.2 million (down 7%) and a net loss of $46.1 million, with $659.7 million in cash and investments at quarter-end before the $250 million October placement. Core products ZEJULA and OPTUNE are shrinking while NUZYRA and XACDURO grow.
Key Events · Earnings and Guidance · ZLAB
-
Q3 Revenue Falls 7% to $108.2M
Total revenue was $108.2 million versus $116.1 million a year ago; product revenue of $107.6 million fell 7% as reported, with ZEJULA down 24% to $32.3 million and OPTUNE down 38% to $7.8 million.
-
Net Loss Widens on Inventory Write-Down
Net loss was $46.1 million, or $0.04 per ordinary share ($0.41 per ADS), versus $36.0 million a year ago, driven primarily by $13.6 million of inventory write-downs in the nine months, mainly VYVGART Hytrulo.
-
Cash of $659.7M Before October Raise
Cash and cash equivalents of $549.7 million plus $100.0 million restricted cash and $10.0 million short-term investments totaled $659.7 million at September 30, 2026, before the $250.0 million gross private placement that closed October 27, 2026.
-
Debt Rises, Nine-Month Burn $133.2M
Short-term debt increased to $252.4 million from $204.5 million at December 31, 2025, while net cash used in operating activities was $133.2 million versus $124.8 million a year ago.
Analysis · ZLAB · Life Sciences
The headline numbers were already out this morning, but the full 10-Q is where the balance sheet shows up: $659.7 million of cash, restricted cash and short-term investments at September 30, before the $250.0 million gross private placement that closed October 27. Against that, short-term debt climbed to $252.4 million from $204.5 million at year-end and the first nine months burned $133.2 million of operating cash, so the October raise buys runway rather than funding growth from a position of strength. The revenue mix is the real story: ZEJULA fell 24% and OPTUNE 38% in the quarter on generic olaparib procurement and glioblastoma competition, offset by NUZYRA up 37% and XACDURO up 31%. A $13.6 million inventory write-down, mostly VYGVART Hytrulo, pushed the net loss to $46.1 million from $36.0 million a year ago.
How filings like this one have moved
In the 30 days to Nov 5, 2026, 33.4% of the 2397 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ZLAB was trading at $23.19 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.9B. The 52-week trading range was $15.96 to $27.50. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.